Stay updated with breaking news from Fitzgerald Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LEXINGTON, Mass. and AMSTERDAM, Sept. 06, 2022 -- uniQure N.V. , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its... | September 6, 2022
LEXINGTON, Mass. and AMSTERDAM, Sept. 06, 2022N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation
10.08.2022 - -First Patient Treated in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy- -Positive One-Year Safety and Efficacy Results From HOPE-2 Open Label Extension Study of CAP-1002 in Non-Ambulant ...
~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington's disease showed the investigative gene therapy was generally well tolerated at this dose with a mean reduction of 53.8% of mutant